WHO recommends malaria vaccine for children at risk
HPS Weekly Report
; 55:41, 2021.
Article
in English
| CAB Abstracts | ID: covidwho-2033648
ABSTRACT
This article is based on a recommendation from an ongoing pilot programme in Ghana, Kenya and Malawi that has reached more than 800,000 children since 2019, with key findings:
(1) The vaccine introduction is feasible, improves health and saves lives, with good and equitable coverage of RTS,S seen through routine immunisation systems. This has occurred even in the context of the COVID-19 pandemic, (2) RTS,S has increased equity in access to malaria prevention, with data from the pilot programme showing that more than two-thirds of children in the three pilot programme countries, who do not sleep under a bednet, have benefitted from the RTS,S vaccine, (3) To date, more than 2.3 million doses of the vaccine have been administered in three African countries, with a favourable safety profile, (4) In areas where the vaccine has been introduced, there has been no decrease in the use of insecticide-treated nets, uptake of other childhood vaccinations, or health seeking behaviour for febrile illness, (5) A reduction of 30% in deadly severe malaria, even when introduced in areas where insecticide-treated nets are widely used and there is good access to diagnosis and treatment, and (6) Modelling estimates that the vaccine is cost-effective in areas of moderate to high malaria transmission. Therefore, this recommendation includes funding decisions from the global health community for broader rollout, and country decision-making on whether to adopt the vaccine as part of national malaria control strategies.
Agencies and Organizations [DD100]; Host Resistance and Immunity [HH600]; Prion, Viral, Bacterial and Fungal Pathogens of Humans [VV210]; Protozoan, Helminth and Arthropod Parasites of Humans [VV220]; children; coronavirus disease 2019; disease control; disease prevention; disease transmission; health protection; human diseases; immune response; immunity; immunization; immunization programmes; malaria; malaria vaccines; mosquito-borne diseases; vaccines; vector-borne diseases; WHO; protozoal infections; parasites; infections; parasitoses; immune sensitization; man; Severe acute respiratory syndrome coronavirus 2; Plasmodium; Kenya; lower-middle income countries; Malawi; ACP Countries; Anglophone Africa; Africa; Commonwealth of Nations; East Africa; Africa South of Sahara; medium Human Development Index countries; Least Developed Countries; low Human Development Index countries; low income countries; SADC Countries; Homo; Hominidae; primates; mammals; vertebrates; Chordata; animals; eukaryotes; Severe acute respiratory syndrome-related coronavirus; Betacoronavirus; Coronavirinae; Coronaviridae; Nidovirales; positive-sense ssRNA Viruses; ssRNA Viruses; RNA Viruses; viruses; Plasmodiidae; Haemospororida; Apicomplexa; Protozoa; immunity reactions; immunological reactions; immunization programs; subsaharan Africa; Nyasaland; SARS-CoV-2; World Health Organization; protozoal diseases; parasitosis; parasitic diseases; parasitic infestations
Search on Google
Collection:
Databases of international organizations
Database:
CAB Abstracts
Type of study:
Prognostic study
Topics:
Vaccines
Language:
English
Journal:
HPS Weekly Report
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS